Emerging role for the Serum Response Factor (SRF) as a potential therapeutic target in cancer

被引：21
作者：
Azam, Haleema [1 ,2 ]
Pierro, Lisa [1 ,2 ]
Reina, Martina [1 ,2 ]
Gallagher, William M. [1 ,2 ]
Prencipe, Maria [1 ,2 ]
机构：
[1] Univ Coll Dublin, UCD Conway Inst, Canc Biol & Therapeut Lab, Dublin D4, Ireland
[2] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland
来源：
EXPERT OPINION ON THERAPEUTIC TARGETS | 2022年 / 26卷 / 02期
基金：
爱尔兰科学基金会;
关键词：
Serum Response Factor (SRF); SRF-inhibitors; CCGs compounds; lestaurtinib; cancer progression; co-factors and co-regulators; hallmarks of cancer; novel therapeutics; prognostic biomarker; transcription factors; C-FOS GENE; ANDROGEN RECEPTOR; HEPATOCELLULAR-CARCINOMA; KINASE INHIBITOR; TRANSCRIPTIONAL REGULATION; TERMINAL PHOSPHORYLATION; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; EXPRESSION; IDENTIFICATION;
D O I：
10.1080/14728222.2022.2032652
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction The Serum Response Factor (SRF) is a transcription factor involved in three hallmarks of cancer: the promotion of cell proliferation, cell death resistance and invasion and metastasis induction. Many studies have demonstrated a leading role in the development and progression of multiple cancer types, thus highlighting the potential of SRF as a prognostic biomarker and therapeutic target, especially for cancers with poor prognosis. Areas covered This review examines the role of SRF in several cancers in promoting cellular processes associated with cancer development and progression. SRF co-factors and signaling pathways are discussed as possible targets to inhibit SRF in a tissue and cancer-specific way. Small-molecule inhibitors of SRF, such as the CCGs series of compounds and lestaurtinib, which could be used as cancer therapeutics, are also discussed. Expert opinion Targeting of SRF and its co-factors represents a promising therapeutic approach. Further understanding of the molecular mechanisms behind the action of SRF could provide a pipeline of novel molecular targets and therapeutic combinations for cancer. Basket clinical trials and the use of SRF immunohistochemistry as companion diagnostics will help testing of these new targets in patients.
引用
收藏
页码：155 / 169
页数：15
相关论文
共 115 条
[11]   The FHL2 regulation in the transcriptional circuitry of human cancers [J].
Cao, Cyanne Ye ;
Mok, Simon Wing-Fai ;
Cheng, Vincent Wing-Sang ;
Tsui, Stephen Kwok-Wing .
GENE, 2015, 572 (01) :1-7
[12]   BAR domain proteins—a linkage between cellular membranes, signaling pathways, and the actin cytoskeleton [J].
Carman P.J. ;
Dominguez R. .
Biophysical Reviews, 2018, 10 (6) :1587-1604
[13]  
Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147
[14]   Inhibitory cardiac transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart failure and attenuated by ventricular unloading [J].
Chang, J ;
Wei, L ;
Otani, T ;
Youker, KA ;
Entman, ML ;
Schwartz, RJ .
CIRCULATION, 2003, 108 (04) :407-413
[15]   Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen [J].
Cheeseman, Matthew D. ;
Chessum, Nicola E. A. ;
Rye, Carl S. ;
Pasqua, A. Elisa ;
Tucker, Michael J. ;
Wilding, Birgit ;
Evans, Lindsay E. ;
Lepri, Susan ;
Richards, Meirion ;
Sharp, Swee Y. ;
Ali, Salyha ;
Rowlands, Martin ;
O'Fee, Lisa ;
Miah, Asadh ;
Hayes, Angela ;
Henley, Alan T. ;
Powers, Marissa ;
te Poele, Robert ;
De Billy, Emmanuel ;
Pellegrino, Loredana ;
Raynaud, Florence ;
Burke, Rosemary ;
van Montfort, Rob L. M. ;
Eccles, Suzanne A. ;
Workman, Paul ;
Jones, Keith .
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (01) :180-201
[16]   Egr-1 is activated by 17β-estradiol in MCF-7 cells by mitogen-activated protein kinase-dependent phosphorylation of ELK-1 [J].
Chen, CC ;
Lee, WR ;
Safe, S .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 93 (05) :1063-1074
[17]   Inhibitory actions of genistein in human breast cancer (MCF-7) cells [J].
Chen, WF ;
Huang, MH ;
Tzang, CH ;
Yang, MS ;
Wong, MS .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2003, 1638 (02) :187-196
[18]  
Coletti D, 2016, EUR J TRANSL MYOL, V26, P87, DOI 10.4081/ejtm.2016.6008
[19]  
Collins C, 2007, CANCER BIOL THER, V6, P1360
[20]   Expression and function of androgen receptor coactivators in prostate cancer [J].
Culig, Z ;
Comuzzi, B ;
Steiner, H ;
Bartsch, G ;
Hobisch, A .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 92 (04) :265-271
12345678910